CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
K Mullanfiroze, A Lazareva, J Chu, L Williams… - Blood …, 2022 - ashpublications.org
Adoptive immunotherapy with chimeric antigen receptor (CAR) T-cell therapy has improved
outcomes in patients with relapse/refractory B-acute lymphoblastic leukemia (r/r B-ALL) …
outcomes in patients with relapse/refractory B-acute lymphoblastic leukemia (r/r B-ALL) …
[HTML][HTML] Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation
Y Zhao, F Gao, J Shi, Y Luo, Y Tan, X Lai, J Yu… - Biology of Blood and …, 2019 - Elsevier
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for both
malignant and nonmalignant hematologic disorders. However, primary poor graft function …
malignant and nonmalignant hematologic disorders. However, primary poor graft function …
[HTML][HTML] CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological …
E Klyuchnikov, J El-Cheikh, A Sputtek… - Biology of blood and …, 2014 - Elsevier
We retrospectively analyzed outcomes of a CD34+-selected stem cell boost (SCB) without
prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with …
prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with …
[HTML][HTML] Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood …
K Raj, DJ Eikema, DP McLornan, E Olavarria… - Biology of Blood and …, 2019 - Elsevier
This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched
donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow …
donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow …
[HTML][HTML] Fresh or cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic …
A Ghobadi, MA Fiala, G Ramsingh, F Gao… - Biology of Blood and …, 2017 - Elsevier
CD34+-selected stem cell boost (SCB) without conditioning has recently been utilized for
poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation with …
poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation with …
Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell …
SP Haen, M Schumm, C Faul, L Kanz… - Journal of cancer …, 2015 - Springer
Purpose Insufficient production of leukocytes, thrombocytes and erythrocytes after
allogeneic peripheral blood stem cell transplantation (PBSCT) represents a life-threatening …
allogeneic peripheral blood stem cell transplantation (PBSCT) represents a life-threatening …
Evolution of stem cell products in medicine: future of off-the-shelf products
P Van Pham, HT Nguyen, NB Vu - Stem cell drugs-a new generation of …, 2018 - Springer
Stem cell transplantation has become the new therapy for various degenerative diseases
(such as Parkinson's disease and spinal cord injury), and even for myocardial infarction …
(such as Parkinson's disease and spinal cord injury), and even for myocardial infarction …
Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature
S Mohammadi, AH Norooznezhad… - … hematology & oncology, 2017 - Springer
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a
valuable approach in treatment of numerous malignant and none malignant hematologic …
valuable approach in treatment of numerous malignant and none malignant hematologic …
Durable engraftment and excellent overall survival after CD34-selected peripheral blood stem cell boost in pediatric patients with poor graft function following …
E Fraint, S Farooki, E Klein, A Mauguen… - … and cellular therapy, 2023 - Elsevier
Poor graft function (PGF) is a life-threatening complication after allogeneic stem cell
transplantation (alloSCT). Historically, outcomes of patients with PGF have been very poor …
transplantation (alloSCT). Historically, outcomes of patients with PGF have been very poor …
Identification, isolation, quantification and systems approach towards CD34, a biomarker present in the progenitor/stem cells from diverse lineages
Mesenchymal stem cells (MSCs) constitute the diverse progenitor populations in almost
every tissue and are of immense importance in the field of regenerative medicine. CD34 is a …
every tissue and are of immense importance in the field of regenerative medicine. CD34 is a …